Table 1: Demographic and baseline characteristics (intention to treat group, ITT).

VariableNitroglycerin( ) Placebo ( ) value

Age (years) 0.98
 Mean (SD)31.7 (5.0)31.7 (5.6)
 Median (range)32 (19; 42)32 (20; 44)

Parity n (%) 0.77
 123 (41.8)24 (42.9)
 2 20 (36.4)22 (39.3)
 310 (18.2)7 (12.5)
 4 0 (0.0)2 (3.6)
 5 2 (3.6)1 (1.8)

Site 1.00
 A11 (20.0)11 (19.6)
 B13 (23.6)14 (25.0)
 C 7 (12.7)8 (14.3)
 D17 (30.9)17 (30.4)
 E7 (12.7)6 (10.7)

Blood loss before treatment (mL)* 0.94
 Mean (SD)554 (464)548 (457)
 Median (range) 450 (50; 2400)450 (0; 2000)

Time from delivery to administration of nitroglycerin or placebo tablets (minutes)* 0.06
 Mean (SD)49.5 (8.9)46.3 (7.5)
 Median (range) 50 (27; 70)46 (31; 62)

Intention to treat group, ITT: all randomized patients, including 4 patients who did not receive study medication and 2 patients who only received 0.5 mg nitroglycerin. *Four patients who did not receive study medication are not included.